Biotech stumbled in FY25, but we didn’t. HB Biotechnology kept its footing and delivered 23% outperformance in a tough market ...

This stock used to be a highflyer but has struggled in recent years as demand waned for its flagship product. Though Moderna ...

If you have $1,000 to invest right now, you may be wondering where to get started. You could buy stocks that are flying high ...

Ardelyx (ARDX) is emerging as a compelling, yet risky, small-cap biotech opportunity. The company has made significant ...

Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Astria Therapeutics ( NASDAQ: ATXS) is a Boston-based pre-commercial biotech developing two late-stage candidates (Navenibart and STAR-0310). The company was initially known as Catabasis ...

Their first product, Illuccix, is a diagnostic imaging agent that allows PET scanners to light up the prostate cancer cells ...

CSL shares have faced several headwinds over the past year. Here's what we can expect next from the biotech business.

Liquidia stock earns the No. 246 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis EXEL, TG Therapeutics TGTX and Inhibrx Biosciences INBX are among the top 5 highly rated ...

Five acquisitions in 2025—including Cargo and Allakos—have put Concentra Biosciences in the spotlight. Learn what’s behind ...

In an interview with Moneycontrol on July 14, Glenn Saldanha, Chairman and Managing Director of Glenmark, discussed the ...

Jack Chan, EY China’s chairman, describes how the HKEX and SFC’s new Technology Enterprises Channel has streamlined the ...